Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine
| Autor: | Jay Suriar Rajasuriar, Hui Ping Lee, Veena Selvaratnam |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
2019-20 coronavirus outbreak COVID-19 Vaccines Thrombotic thrombocytopenic purpura Case Report haematology (drugs and medicines) Gastroenterology Internal medicine hemic and lymphatic diseases ChAdOx1 nCoV-19 Medicine Humans Microangiopathic haemolytic anaemia thrombotic thrombocytopenic purpura Vaccines Plasma Exchange Purpura Thrombotic Thrombocytopenic business.industry immunological products and vaccines Autoantibody COVID-19 General Medicine Left upper limb Middle Aged medicine.disease ADAMTS13 Peripheral blood Rituximab Female business medicine.drug |
| Zdroj: | BMJ Case Reports |
| ISSN: | 1757-790X |
| Popis: | A 50-year-old Indian woman presented with acute dysphasia, left upper limb numbness and thrombocytopenia 12 days after receiving the ChAdOx1 nCoV-19 vaccine (AstraZeneca/Vaxzevria). MRI of the brain was unremarkable. Microangiopathic haemolytic anaemia with thrombocytopenia was noted on her peripheral blood film. A diagnosis of thrombotic thrombocytopenic purpura (TTP) was confirmed through the findings of absent ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity and markedly raised titre of ADAMTS13 autoantibodies. Prompt treatment with plasma exchange, adjunctive steroids and rituximab was commenced. A remission of TTP was achieved and she was discharged 3 weeks after admission. While other immune-mediated conditions have been documented after receipt of the vaccine, this report highlights the first case of immune-mediated TTP diagnosed after administration of the ChAdOx1 nCoV-19 vaccine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|